TTNP TITAN PHARMA INC

2.85
+0  (2%)
Previous Close 2.80
Open 2.80
Price To book 4.50
Market Cap 60.41M
Shares 21,198,000
Volume 41,003
Short Ratio 16.46
Av. Daily Volume 89,145

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

Latest News

  1. ETFs with exposure to Titan Pharmaceuticals, Inc. : April 20, 2017
  2. ETFs with exposure to Titan Pharmaceuticals, Inc. : March 27, 2017
  3. TTNP: 2016 Results; Deep Dive on Development Programs
  4. Titan Pharmaceuticals, Inc. :TTNP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
  5. Titan Pharmaceuticals reports 4Q loss
  6. Titan Pharmaceuticals Reports Full Year And Fourth Quarter 2016 Financial Results
  7. Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2016 Financial Results
  8. Titan Pharmaceuticals To Present At 29th Annual ROTH Conference
  9. Titan Pharmaceuticals Receives FDA Communication On Ropinirole Implant Investigational New Drug Application
  10. Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
  11. Braeburn Pharmaceuticals' Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services
  12. Titan Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
  13. Titan Pharmaceuticals Appoints Two New Board Members
  14. Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year
  15. Titan Pharmaceuticals Reports Third Quarter 2016 Financial Results
  16. Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2016 Financial Results
  17. Probuphine® Implant for Opioid Dependence Featured at 2016 International Society of Addiction Medicine Meeting
  18. Braeburn Pharmaceuticals to Conduct Series of Probuphine® (buprenorphine) Implant Trainings in Salt Lake City on October 27-29, 2016 for Qualified Healthcare Providers
  19. Braeburn Pharmaceuticals to Conduct Series of Probuphine® (buprenorphine) Implant Trainings in Baltimore on October 26-28, 2016 for Qualified Healthcare Providers

SEC Filings

  1. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17769837
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17693515
  3. 8-K - Current report 17683175
  4. 8-K - Current report 17644251
  5. 8-K - Current report 17639503
  6. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17592921
  7. 8-K - Current report 17515828
  8. 8-K - Current report 17503655
  9. 8-K - Current report 162002886
  10. 10-Q - Quarterly report (Sections 13 or 15(d)) 161982885